Cell Therapy Landscape Evolves as Major Players Persist Amid Industry Exodus
In the wake of high-profile departures from the cell therapy space, including Takeda and Novo Nordisk, a core group of pharmaceutical giants and emerging biotechs continue to push the boundaries of this innovative treatment modality. Despite recent setbacks, companies like Bristol Myers Squibb, Gilead, and Johnson & Johnson are doubling down on their investments, while smaller players such as Immatics, Kyverna Therapeutics, and Cabaletta Bio are making significant strides in expanding cell therapy applications beyond oncology.
